Jeevan Scienti.

Who are in the management team of Jeevan Scienti.?

As of March 2021, the management team of Jeevan Scienti includes K Krishna Kishore (Vice Chairman & Managing Director), T Ravi Babu, G Bhanu Prakash, Koteswara Rao SSR (Chairman & Independent Director), K Rama Krishna Prasad, Snigdha Mothukuri (Executive Director & CEO), K. Jeevan Krishna, Sharvari Swapnil Shinde (Company Secretary), and Nageswar Rao Yarllagadda. This team oversees the company's operations and strategic direction.

As of March 2021, the management team of Jeevan Scienti includes the following members:<BR><BR>1. K Krishna Kishore - Vice Chairman & Managing Director<BR>2. T Ravi Babu - Director<BR>3. G Bhanu Prakash - Independent Director<BR>4. Koteswara Rao SSR - Chairman & Independent Director<BR>5. K Rama Krishna Prasad - Director<BR>6. Snigdha Mothukuri - Executive Director & CEO<BR>7. K. Jeevan Krishna - Director<BR>8. Sharvari Swapnil Shinde - Company Secretary<BR>9. Nageswar Rao Yarllagadda - Director<BR><BR>This team is responsible for overseeing the company's operations and strategic direction.

Has Jeevan Scienti. declared dividend?

Jeevan Scientific Technology Ltd has declared a 12% dividend, amounting to ₹1.2 per share, with an ex-date of September 21, 2022. Despite the dividend declaration, the company has experienced significant negative total returns over shorter periods, though it saw a positive return of 122.3% over the past five years.

Jeevan Scientific Technology Ltd has declared a 12% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 12%<BR>- Amount per share: 1.2<BR>- Ex-date: 21 Sep 22<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the 6-month period, the price return was -23.55%, with a dividend return of 0%, resulting in a total return of -23.55%.<BR><BR>For the 1-year period, the price return was -17.17%, with a dividend return of 0%, leading to a total return of -17.17%.<BR><BR>Over the 2-year period, the price return was -7.49%, and the dividend return was 0%, resulting in a total return of -7.49%.<BR><BR>In the 3-year period, the price return was -36.89%, with a dividend return of 2.09%, culminating in a total return of -34.8%.<BR><BR>For the 4-year period, the price return was -55.82%, and the dividend return was 1.95%, leading to a total return of -53.87%.<BR><BR>Over the 5-year period, the price return was 113.4%, with a dividend return of 8.90%, resulting in a total return of 122.3%.<BR><BR>Overall, while Jeevan Scientific Technology Ltd has declared a dividend, the total returns over various periods show significant volatility, with negative returns dominating in shorter time frames, though there was a substantial positive return over the 5-year period.

Who are the peers of the Jeevan Scienti.?

Peers of Jeevan Scienti. include Syngene Intl., Dr Lal Pathlabs, Poly Medicure, Indegene, Vijaya Diagnost., Aspira Pathlab, N G Industries, Centennial Surgic, and Deccan Healthcare. In terms of returns, Aspira Pathlab leads with 80.64% over one year, while Jeevan Scienti. has a return of -19.28%.

Peers: The peers of Jeevan Scienti. are Syngene Intl., Dr Lal Pathlabs, Poly Medicure, Indegene, Vijaya Diagnost., Aspira Pathlab, N G Industries, Centenial Surgic, Deccan Healthcar.<BR><BR>Quality Snapshot: Excellent management risk is observed at Dr Lal Pathlabs, while Good management risk is found at Syngene Intl., Poly Medicure, Indegene, and Vijaya Diagnost., and the rest have Below Average or Average management risk. Growth is Excellent at Bandaram Pharma, while Average growth is seen at Indegene and Poly Medicure, and the rest exhibit Below Average growth. Capital Structure is Excellent at Syngene Intl., Dr Lal Pathlabs, Poly Medicure, Indegene, Vijaya Diagnost., and the rest have Average or Below Average capital structure.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Aspira Pathlab at 80.64%, while the lowest is Syngene Intl. at -3.70%, and Jeevan Scienti.'s own 1-year return is -19.28%, which is lower than both. Additionally, peers such as Syngene Intl., Poly Medicure, Vijaya Diagnost., Aspira Pathlab, N G Industries, Centenial Surgic, Deccan Healthcar, and Bandaram Pharma have negative six-month returns.

What is the technical trend for Jeevan Scienti.?

As of June 2, 2025, Jeevan Scienti's technical trend has shifted to a moderate bearish stance, supported by bearish signals from MACD, Bollinger Bands, moving averages, and KST indicators across multiple time frames.

As of 2 June 2025, the technical trend for Jeevan Scienti has changed from mildly bearish to bearish. The current stance is bearish with a moderate strength. The weekly MACD is mildly bullish, but the monthly MACD is bearish, indicating mixed signals. The Bollinger Bands are bearish on both weekly and monthly time frames, reinforcing the bearish outlook. Daily moving averages are also bearish, and both the weekly and monthly KST are bearish, further supporting the negative trend. The Dow Theory indicates a mildly bearish stance on both weekly and monthly charts. Overall, the combination of these indicators suggests a bearish sentiment in the market for Jeevan Scienti.

What does Jeevan Scienti. do?

Jeevan Scientific Technology Ltd is an independent clinical contract research organization providing technology-driven clinical research solutions. As of March 2025, it reported net sales of 101 Cr and a net loss of 13 Cr, with a market cap of INR 63 Cr.

Overview:<BR>Jeevan Scientific Technology Ltd is an Independent Clinical Contract Research Organization in the Healthcare Services industry, operating within the Micro Cap market-cap bracket, providing reliable and technology-driven clinical research solutions.<BR><BR>History:<BR>The company was incorporated on 2nd February, 1999, originally as Jeevan Softech Limited. It has maintained its status as a clinical research organization, with the latest reported quarterly results for net sales and profit being for March 2025.<BR><BR>Financial Snapshot:<BR>Net Sales: 101 Cr (Quarterly Results - Mar 2025)<BR>Net Profit: -13 Cr (Quarterly Results - Mar 2025)<BR>Market Cap: INR 63 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 63.00<BR>Industry P/E: 37<BR>Dividend Yield: 0.00%<BR>Debt-Equity: 0.41<BR>Return on Equity: 0.28%<BR>Price to Book: 1.27<BR><BR>Contact Details:<BR>Address: Plot 1 & 2 Sai Krupa Enclave, Manikonda Jagir Nr Lanco Hills Hyderabad Telangana : 500008<BR>Tel: 91-40-67364700<BR>Email: info@jeevanscientific.com<BR>Website: http://www.jeevanscientific.com

Who are the top shareholders of the Jeevan Scienti.?

The top shareholders of Jeevan Scienti are Krishna Kishore Kuchipudi with 12.22% and Durisala Desaiah with 5.24%. Individual investors hold a combined 42.99%, with no mutual funds or foreign institutional investors involved, and no pledged promoter holdings.

The top shareholders of Jeevan Scienti include Krishna Kishore Kuchipudi, who holds the highest promoter stake at 12.22%. The highest public shareholder is Durisala Desaiah, with a holding of 5.24%. Additionally, individual investors collectively hold 42.99% of the company's shares. There are no mutual funds or foreign institutional investors currently holding shares in the company, and there are no pledged promoter holdings.

How big is Jeevan Scienti.?

As of 24th July, Jeevan Scientific Technology Ltd has a market capitalization of 64.00 Cr, with recent net sales of 46.85 Cr and a net profit of 0.14 Cr. The balance sheet for March 2024 shows shareholder's funds of 48.43 Cr and total assets of 66.95 Cr.

As of 24th July, Jeevan Scientific Technology Ltd has a market capitalization of 64.00 Cr, classified as a Micro Cap.<BR><BR>In the latest 4 quarters, the company reported Net Sales of 46.85 Cr and a Net Profit of 0.14 Cr.<BR><BR>The latest annual period for the balance sheet is March 2024, showing Shareholder's Funds of 48.43 Cr and Total Assets of 66.95 Cr.

Is Jeevan Scienti. overvalued or undervalued?

As of August 18, 2025, Jeevan Scienti. is considered overvalued and risky due to a negative PE ratio of -15.40, an EV to EBITDA ratio of 34.18, a low ROCE of 1.66%, and underperformance compared to peers and the Sensex.

As of 18 August 2025, the valuation grade for Jeevan Scienti. has moved from very attractive to risky, indicating a significant shift in its perceived value. The company appears to be overvalued based on its current metrics, particularly with a PE ratio of -15.40 and an EV to EBITDA ratio of 34.18, which are concerning indicators of financial health. Additionally, the ROCE stands at a mere 1.66%, further underscoring the company's struggles to generate returns.<BR><BR>When comparing Jeevan Scienti. to its peers, it stands out negatively. For instance, Sun Pharma. has a PE ratio of 34.14 and an EV to EBITDA of 23.11, while Cipla shows a PE of 23.52 and an EV to EBITDA of 16.57, both of which are significantly more favorable. The company's stock has also underperformed relative to the Sensex, with a year-to-date return of -20.48% compared to the Sensex's 4.01%. Overall, Jeevan Scienti. is assessed as overvalued given its poor financial ratios and relative performance against industry peers.

When is the next results date for Jeevan Scienti.?

Jeevan Scienti. will declare its results on 12 November 2025.

Jeevan Scienti. will declare its results on 12 November 2025.

How has been the historical performance of Jeevan Scienti.?

Jeevan Scienti's historical performance shows fluctuating financial metrics, with net sales rising to 46.84 Cr in Mar'25 from 36.18 Cr in Mar'23, but still below the peak of 67.79 Cr in Mar'22. Operating profit improved to 8.06 Cr in Mar'25, while profit before and after tax returned to positive figures, indicating a recovery despite increased total assets and liabilities.

Answer:<BR>The historical performance of Jeevan Scienti shows a fluctuating trend in key financial metrics over the years.<BR><BR>Breakdown:<BR>Jeevan Scienti's net sales have seen a rise from 36.18 Cr in Mar'23 to 46.84 Cr in Mar'25, although they peaked at 67.79 Cr in Mar'22. The total operating income followed a similar pattern, increasing to 46.84 Cr in Mar'25 from 39.65 Cr in Mar'24, yet it remains below the 67.79 Cr recorded in Mar'22. The company's operating profit (PBDIT) has improved significantly, reaching 8.06 Cr in Mar'25 from 5.29 Cr in Mar'24, but it is still a decline from the 22.67 Cr in Mar'22. Profit before tax has shown a recovery to 0.05 Cr in Mar'25 from a loss of 1.60 Cr in Mar'24, while profit after tax also returned to a positive figure of 0.06 Cr in Mar'25, compared to a loss of 1.33 Cr in the previous year. The total assets of the company increased to 77.37 Cr in Mar'25 from 66.95 Cr in Mar'24, reflecting a growth trend, while total liabilities also rose to 77.37 Cr from 66.95 Cr, indicating a proportional increase in debt levels. Cash flow from operating activities improved to 10.00 Cr in Mar'25 from 2.00 Cr in Mar'24, showcasing a positive shift in cash generation capabilities.

Are Jeevan Scientific Technology Ltd latest results good or bad?

Jeevan Scientific Technology Ltd's latest Q3 FY26 results show a positive turnaround with a net profit of ₹1.42 crores and a 54.04% revenue growth, but concerns remain about its long-term financial health and weak return on equity, leading to a "SELL" advisory score.

Jeevan Scientific Technology Ltd's latest results for Q3 FY26 indicate a significant improvement in performance, marking a positive turnaround from previous quarters. The company reported a net profit of ₹1.42 crores, returning to profitability after a loss in the previous quarter. Revenue saw a remarkable growth of 54.04% quarter-on-quarter and 52.44% year-on-year, reaching ₹19.07 crores, which is the highest quarterly revenue in its recent history.<BR><BR>Additionally, the operating margin improved to 27.43%, the best performance in four quarters, suggesting enhanced operational efficiency. However, despite these positive indicators, the company remains loss-making on a trailing twelve-month basis, and its return on equity (ROE) is relatively weak at 9.56%. The overall advisory score places it in "SELL" territory, reflecting concerns about its long-term financial health.<BR><BR>In summary, while the latest results show strong revenue growth and a return to profitability, there are underlying concerns regarding the company's overall financial stability and capital efficiency. Investors should consider these factors when evaluating the company's performance.

Should I buy, sell or hold Jeevan Scientific Technology Ltd?

Why is Jeevan Scientific Technology Ltd falling/rising?

As of 04-Mar, Jeevan Scientific Technology Ltd's stock price is declining to Rs 67.51, down 4.13% after a trend reversal. The stock is underperforming its sector and has seen a significant drop in investor participation, indicating a bearish trend.

As of 04-Mar, Jeevan Scientific Technology Ltd's stock price is falling, currently at Rs 67.51, which represents a decrease of Rs 2.91 or 4.13%. This decline follows a trend reversal after four consecutive days of gains. The stock has underperformed its sector by 3.04% today, indicating weaker performance relative to its peers. Additionally, the stock reached an intraday low of Rs 67.51, suggesting significant selling pressure.<BR><BR>Investor participation has also decreased, with delivery volume dropping by 81.26% compared to the 5-day average, indicating reduced interest from investors. Although the stock remains above its 5-day, 50-day, 100-day, and 200-day moving averages, it is below the 20-day moving average, which may signal a bearish trend. Overall, these factors contribute to the current decline in the stock price of Jeevan Scientific Technology Ltd.

Which are the latest news on Jeevan Scienti.?